Literature DB >> 17685471

Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure.

William Bernal1, Catherine Hall, Constantine J Karvellas, Georg Auzinger, Elizabeth Sizer, Julia Wendon.   

Abstract

UNLABELLED: High circulating ammonia concentrations are common in patients with acute liver failure (ALF) and are associated with hepatic encephalopathy (HE) and intracranial hypertension (ICH). Other risk factors are poorly characterized. We evaluated the relation of the admission arterial ammonia concentration and other clinical variables with the development of HE and ICH. Arterial ammonia was measured on admission to the intensive care unit in 257 patients; 165 had ALF and severe HE, and there were 3 control groups: acute hepatic dysfunction without severe HE (n = 50), chronic liver disease (n = 33), and elective surgery (n = 9). Variables associated with ICH and HE were investigated with regression analysis. Ammonia was higher in ALF patients than controls. An independent risk factor for the development of severe HE and ICH, a level greater than 100 mumol/L predicted the onset of severe HE with 70% accuracy. The model for end-stage liver disease (MELD) score was also independently predictive of HE, and its combination with ammonia increased specificity and accuracy. ICH developed in 55% of ALF patients with a level greater than 200 mumol/L, although this threshold failed to identify most cases. After admission, ammonia levels remained high in those developing ICH and fell in those who did not. Youth, a requirement for vasopressors, and renal replacement therapy were additional independent risk factors.
CONCLUSION: Ammonia is an independent risk factor for the development of both HE and ICH. Additional MELD scoring improved the prediction of HE. Factors other than ammonia also appear important in the pathogenesis of ICH. Ammonia measurements could form part of risk stratification for HE and ICH, identifying patients for ammonia-lowering therapies and invasive monitoring.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17685471     DOI: 10.1002/hep.21838

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  93 in total

Review 1.  Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

Authors:  Amit S Seyan; Robin D Hughes; Debbie L Shawcross
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

Review 2.  Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited.

Authors:  Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2015-11-02       Impact factor: 3.584

3.  Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.

Authors:  R Todd Stravitz; Michelle Gottfried; Valerie Durkalski; Robert J Fontana; A James Hanje; David Koch; Bilal Hameed; Daniel Ganger; Ram M Subramanian; Stan Bukofzer; William R Ravis; Kristen Clasen; Averell Sherker; Lanna Little; William M Lee
Journal:  Hepatology       Date:  2018-01-30       Impact factor: 17.425

Review 4.  Therapeutic hypothermia as a bridge to transplantation in patients with fulminant hepatic failure.

Authors:  Luis Castillo; Guillermo Bugedo; Max Rovegno
Journal:  Rev Bras Ter Intensiva       Date:  2015-03-01

Review 5.  Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation.

Authors:  Dominic R Aldridge; Edward J Tranah; Debbie L Shawcross
Journal:  J Clin Exp Hepatol       Date:  2014-06-30

Review 6.  Changes in cerebral oxidative metabolism in patients with acute liver failure.

Authors:  P N Bjerring; F S Larsen
Journal:  Metab Brain Dis       Date:  2012-10-26       Impact factor: 3.584

7.  A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.

Authors:  Ganesh Pantham; Anthony Post; Deepak Venkat; Douglas Einstadter; Kevin D Mullen
Journal:  Dig Dis Sci       Date:  2017-05-30       Impact factor: 3.199

Review 8.  Systemic inflammation and ammonia in hepatic encephalopathy.

Authors:  Thomas H Tranah; Godhev K Manakkat Vijay; Jennifer M Ryan; Debbie L Shawcross
Journal:  Metab Brain Dis       Date:  2012-12-07       Impact factor: 3.584

Review 9.  Therapeutic hypothermia for acute liver failure: toward a randomized, controlled trial in patients with advanced hepatic encephalopathy.

Authors:  R Todd Stravitz; William M Lee; Andreas H Kramer; David J Kramer; Linda Hynan; Andres T Blei
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

10.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.